Genmab A/S GMAB
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Net income | $963.0M | -15% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Research & development | $1.6B | +14% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 10 open-market buys ($7.6B) and 0 sales ($0) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| A/S Genmab10% owner | Bought | 75,867,199 | $97.00 | $7.4B | Dec 29, 2025 |
| A/S Genmab10% owner | Bought | 1,052,806 | $97.00 | $102.1M | Dec 29, 2025 |
| A/S Genmab10% owner | Bought2 fills | 145,588 | $97.00 avg | $14.1M | Dec 26, 2025 |
| A/S Genmab10% owner | Bought | 96,082 | $97.00 | $9.3M | Dec 24, 2025 |
| A/S Genmab10% owner | Bought | 561,042 | $97.00 | $54.4M | Dec 23, 2025 |
| A/S Genmab10% owner | Bought | 15,710 | $97.00 | $1.5M | Dec 22, 2025 |
| A/S Genmab10% owner | Bought | 66,264 | $97.00 | $6.4M | Dec 19, 2025 |
| A/S Genmab10% owner | Bought | 212,177 | $97.00 | $20.6M | Dec 18, 2025 |
| A/S Genmab10% owner | Bought | 150,795 | $97.00 | $14.6M | Dec 17, 2025 |
| A/S Genmab10% owner | Bought | 120,752 | $97.00 | $11.7M | Dec 16, 2025 |
Trades by members of Congress
1 member reported 1 buy and 1 sale since Dec 16, 2024. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Josh Gottheimer D | Bought | $1,001–$15K | Jan 16, 2025 | Feb 10, 2025 | Joint |
| Josh Gottheimer D | Sold | $1,001–$15K | Dec 16, 2024 | Jan 14, 2025 | Joint |
Latest SEC filings
- News filing (foreign) 6-K · Oct 28, 2026
- News filing (foreign) 6-K · Oct 23, 2026
- News filing (foreign) 6-K · Oct 13, 2026
- News filing (foreign) 6-K · Oct 7, 2026
- News filing (foreign) 6-K · Oct 5, 2026
- News filing (foreign) 6-K · Oct 2, 2026
- News filing (foreign) 6-K · Sep 29, 2026
- News filing (foreign) 6-K · Sep 24, 2026
- News filing (foreign) 6-K · Sep 9, 2026
- News filing (foreign) 6-K · Sep 9, 2026
- News filing (foreign) 6-K · Sep 8, 2026
- News filing (foreign) 6-K · Aug 12, 2026
- News filing (foreign) 6-K · Aug 11, 2026
- News filing (foreign) 6-K · Aug 6, 2026
- News filing (foreign) 6-K · Jul 15, 2026
- News filing (foreign) 6-K · Jun 29, 2026
- News filing (foreign) 6-K · Jun 17, 2026
- News filing (foreign) 6-K · Jun 16, 2026
- News filing (foreign) 6-K · Jun 15, 2026
- News filing (foreign) 6-K · Jun 15, 2026
- News filing (foreign) 6-K · Jun 11, 2026
- News filing (foreign) 6-K · May 29, 2026
- News filing (foreign) 6-K · May 13, 2026
- News filing (foreign) 6-K · May 12, 2026
- News filing (foreign) 6-K · May 8, 2026
About Genmab A/S
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- 1253 Copenhagen K, Denmark
- Exchange
- Nasdaq
- Also trades as
- GNMSF
- Filer size
- Large accelerated filer
- SEC company number (CIK)
- 1434265
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.